Stifel raised the firm’s price target on Guardant Health (GH) to $130 from $120 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $135 from $125 at Canaccord
- Guardant Health price target raised to $150 from $135 at Citi
- Guardant Health price target raised to $130 from $120 at Barclays
- Guardant Health reports Q4 EPS (50c), consensus (47c)
- Guardant Health sees FY26 revenue $1.25B-$1.28B, consensus $1.24B